These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30802200)

  • 1. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
    Dawra VK; Liang Y; Shi H; Bass A; Hickman A; Terra SG; Zhou S; Cutler D; Sahasrabudhe V
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):207-216. PubMed ID: 30802200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.
    Dawra VK; Pelletier K; Matschke K; Shi H; Hickman A; Zhou S; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2021 May; 10(5):510-520. PubMed ID: 33135865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects.
    Li Y; Nucci G; Yamamoto Y; Fediuk DJ; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):765-776. PubMed ID: 33434408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects.
    Li Y; Mu Y; Shi H; Liang Y; Liu Z; Matschke K; Hickman A; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):97-106. PubMed ID: 30934166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
    Dawra VK; Liang Y; Wei H; Pelletier K; Shi H; Hickman A; Bass A; Terra SG; Zhou S; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):50-61. PubMed ID: 31207178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Rifampin on the Pharmacokinetics of Ertugliflozin in Healthy Subjects.
    Dawra VK; Sahasrabudhe V; Liang Y; Matschke K; Shi H; Hickman A; Saur D; Terra SG; Cutler DL
    Clin Ther; 2018 Sep; 40(9):1538-1547. PubMed ID: 30170758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
    Fediuk DJ; Nucci G; Dawra VK; Cutler DL; Amin NB; Terra SG; Boyd RA; Krishna R; Sahasrabudhe V
    Clin Pharmacokinet; 2020 Aug; 59(8):949-965. PubMed ID: 32337660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects.
    Macha S; Brand T; Meinicke T; Link J; Broedl UC
    Clin Ther; 2015 Aug; 37(8):1789-96. PubMed ID: 26138865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
    Fediuk DJ; Zhou S; Dawra VK; Sahasrabudhe V; Sweeney K
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):696-706. PubMed ID: 33205593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment.
    Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL
    Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed-Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin.
    Sahasrabudhe V; Fediuk DJ; Matschke K; Shi H; Liang Y; Hickman A; Bass A; Terra SG; Zhou S; Krishna R; Dawra VK
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):619-627. PubMed ID: 30427588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects.
    Dawra VK; Cutler DL; Zhou S; Krishna R; Shi H; Liang Y; Alvey C; Hickman A; Saur D; Terra SG; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2019 Apr; 8(3):314-325. PubMed ID: 29786959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin.
    Raje S; Callegari E; Sahasrabudhe V; Vaz A; Shi H; Fluhler E; Woolf EJ; Schildknegt K; Matschke K; Alvey C; Zhou S; Papadopoulos D; Fountaine R; Saur D; Terra SG; Stevens L; Gaunt D; Cutler DL
    Clin Transl Sci; 2018 Jul; 11(4):405-411. PubMed ID: 29575530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form.
    Sahasrabudhe V; Matschke K; Shi H; Hickman A; Kong A; Rodríguez Spong B; Nickerson B; Arora KK
    Int J Clin Pharmacol Ther; 2022 Jul; 60(7):317-326. PubMed ID: 35575420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
    Dagogo-Jack S; Liu J; Eldor R; Amorin G; Johnson J; Hille D; Liao Y; Huyck S; Golm G; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 Mar; 20(3):530-540. PubMed ID: 28921862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
    Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
    Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence of Ertugliflozin/Sitagliptin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
    Fediuk DJ; Matschke K; Liang Y; Pelletier KB; Wei H; Shi H; Bass A; Hickman A; Terra SG; Zhou S; Krishna R; Sahasrabudhe V
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):884-894. PubMed ID: 31219248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No apparent pharmacokinetic interactions were found between henagliflozin: A novel sodium-glucose co-transporter 2 inhibitor and glimepiride in healthy Chinese male subjects.
    Que L; Huang K; Xiang X; Ding Y; Chu N; He Q
    J Clin Pharm Ther; 2022 Aug; 47(8):1225-1231. PubMed ID: 35362180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
    Aronson R; Frias J; Goldman A; Darekar A; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Jun; 20(6):1453-1460. PubMed ID: 29419917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations.
    Fediuk DJ; Sahasrabudhe V; Dawra VK; Zhou S; Sweeney K
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1297-1306. PubMed ID: 34213819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.